Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat in pediatric anemia associated with chronic kidney disease
NCT05682326Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of daprodustat in anemia, sponsored by GSK. Primary endpoints: Adverse Events at 56 weeks, Serious Adverse Events at 56 weeks and 2 more. Started Sep 2023; status: completed.
02
Drugs
daprodustat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05682326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682326.